Increasing Parasitic Infections To Drive Market Growth For Anthelmintic Drugs Is Supporting Development Across The Anthelmintic Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Anthelmintic Drugs Market Over The Forecast Period?

The anthelmintic drugs market size has experienced strong growth in recent years. It is anticipated to expand from $3.34 billion in 2025 to $3.53 billion in 2026, at a compound annual growth rate (CAGR) of 5.5%. This historical growth can be attributed to several factors, including the high prevalence of parasitic infections, limited access to advanced anthelmintic drugs, a reliance on traditional drug classes, increasing awareness of helminth infections, and the expanding infrastructure of hospitals and clinics.

The anthelmintic drugs market is projected to experience robust expansion over the coming years. This market is set to reach a valuation of $4.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the forecast period include the introduction of new anthelmintic compounds, greater use of combined treatment approaches, a surge in veterinary and livestock applications, the widening reach of online and retail pharmacies, and governmental efforts in parasite eradication schemes. Key trends anticipated within the same period encompass the increasing occurrence of helminthic infections across human and animal populations, a rise in the uptake of oral and injectable anthelmintic formulations, augmented demand for veterinary anthelmintics in livestock care, the broadened presence of retail and internet-based pharmacy channels for these medications, and an emphasis on combination treatments and wide-ranging anthelmintic solutions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19291&type=smp

Which Significant Factors Are Encouraging Growth In The Anthelmintic Drugs Market?

The significant occurrence of parasitic infections is anticipated to propel the expansion of the anthelmintic drugs market moving forward. Parasitic infections refer to diseases caused by organisms, such as protozoa, worms, or ectoparasites, that inhabit another host. These infections are exacerbated by poor sanitation, tainted food or water, close interaction with infected individuals or animals, insufficient hygiene, and restricted availability of clean resources. Anthelmintic drugs are employed to address infections stemming from parasitic worms, effectively targeting and eliminating these parasites from the host’s body. These medications operate by disrupting the parasites’ physiological functions, which results in their expulsion or death. For instance, in September 2025, as per information published by the Centers for Disease Control and Prevention, a US-based national public health agency, by September 16, 2025, the CDC had documented reports of 990 cases of cyclosporiasis acquired within the United States. Hence, the widespread incidence of parasitic infections is fostering the growth of the anthelmintic drugs market.

What Segment Types Are Included In The Anthelmintic Drugs Market Analysis?

The anthelmintic drugs market covered in this report is segmented –

1) By Drug Class: Benzimidazoles, Macrocyclic lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Other Drug Classes

2) By Route Of Administration: Oral, Injectable

3) By Infection Type: Nematode Infections, Cestode Infections, Trematode Infections, Mixed Infections

4) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Online Pharmacies, Veterinary Clinics And Supply Stores

5) By Application: Human Anthelmintics, Veterinary Anthelmintics

Subsegments:

1) By Benzimidazoles: Albendazole, Mebendazole, Fenbendazole, Oxfendazole, Thiabendazole

2) By Macrocyclic Lactones: Ivermectin, Moxidectin, Doramectin, Eprinomectin, Milbemycin Oxime

3) By Pyrazinoisoquinolones: Praziquantel, Cysticide

4) By Tetrahydropyrimidines: Pyrantel Pamoate, Pyrantel Tartrate

5) By Other Drug Classes: Imidazothiazoles, Aminoacetonitrile Derivatives, Spiroindoles, Arsenicals

Which Trends Are Shaping The Anthelmintic Drugs Market Landscape?

Companies within the anthelmintic drugs market are concentrating on developing innovative solutions, such as targeted, evidence-based deworming programs, to enhance parasite control, reduce drug resistance, and foster the sustainable use of anthelmintics, departing from traditional blanket deworming methods that often rely on frequent, untargeted treatments. These targeted deworming programs employ diagnostic testing, parasite load assessment, and strategic dosing schedules to optimize treatment efficacy while minimizing environmental and resistance risks. For example, in April 2025, Zoetis Inc., a US-based animal health company, introduced its “Buy Less Dewormer” campaign specifically for equine populations, advocating for evidence-based parasite management. The program integrates educational resources with guidance on fecal egg count monitoring and strategic anthelmintic selection. It functions by encouraging horse owners and veterinarians to administer treatments only when necessary, based on an assessment of parasite burden and risk. Unique features of this initiative include integrated educational materials, risk-based treatment recommendations, and support for sustainable anthelmintic stewardship. Its applications cover equine herd health management, the prevention of parasite resistance, and the optimization of deworming schedules. The benefits realized include a reduction in anthelmintic overuse, improved parasite control outcomes, lower costs for owners, and the promotion of long-term drug efficacy.

Who Are The Key Market Participants In The Anthelmintic Drugs Market?

Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company

Access The Complete Anthelmintic Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/anthelmintic-drugs-global-market-report

Which Region Commands The Largest Share Of The Anthelmintic Drugs Market?

North America was the largest region in the anthelmintic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthelmintic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Anthelmintic Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=19291&type=smp

Browse Through More Reports Similar to the Global Anthelmintic Drugs Market 2026, By The Business Research Company

Kidney Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Ovarian Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795